No Picture
Los Angeles Biotech Trending News

ImmPACT Bio Closes $111 Million Series B Financing, Names New Board Chair and New President and CEO, and Updates on Phase 1 Clinical Study in Relapsed/Refractory B-cell Non-Hodgkin’s Lymphoma

CAMARILLO, Calif.: CAMARILLO, Calif., Jan. 20, 2022 /PRNewswire/ — ImmPACT Bio USA, Inc. ("ImmPACT Bio"), a clinical-stage company developing transformative logic-gate based chimeric antigen receptor (CAR) T-cell therapies for treating cancer, today announced it has […]

No Picture
News

Crystallography for the Misfit Crystals

As the name implies, crystallography requires crystals – specifically, purified samples of the molecule of interest, coaxed into a crystal form. But most molecules form powders composed of jumbled granules, not picture-ready crystals. A new […]

No Picture
Boston Cambridge Biotech Trending News

FDA+ roundup: FDA’s neuroscience deputy departs amid ongoing Aduhelm investigations; Califf on the ropes?

Amid increased scrutiny into the close ties between FDA and Biogen prior to the controversial accelerated approval of Aduhelm, the deputy director of the FDA’s office of neuroscience has called it quits after more than […]

No Picture
News

Nanoscope’s Vision Restoring Optogenetic Gene Therapy to be Featured in Four Presentations as part of SPIE Photonics West 2022 in San Francisco Jan. 22-27, 2022

BEDFORD, Texas: BEDFORD, Texas, Jan. 19, 2022 /PRNewswire/ — Nanoscope Therapeutics Inc., a clinical-stage biotechnology company developing optogenetic gene therapies for the treatment of retinal degenerative diseases, will be featured in several presentations at BiOS, […]

No Picture
News

Neurophth Therapeutics Receives IND Clearance to Initiate Clinical Trial for China AAV-ND4 Gene Therapy NR082 in Leber Hereditary Optic Neuropathy

WUHAN, China and SAN DIEGO: WUHAN, China and SAN DIEGO, Jan. 19, 2022 /PRNewswire/ — Neurophth Therapeutics, Inc., (hereinafter referred to as "Neurophth"), today announced receiving the U.S. Food and Drug Administration (FDA) clearance of […]